IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
Subscribe To Our Newsletter & Stay Updated
